ARTICLES BY ERIN HARRIS
Diversity And Inclusion In The Cell And Gene Sector
Aman Khera, Global Head of Regulatory Strategy at Worldwide Clinical Trials answers my questions about the state of diversity and inclusion specifically in the cell and gene sector.
Inside Sangamo’s Decision to Build an In-House AAV Manufacturing Facility
Andy Ramelmeier, EVP Technical Operations at Sangamo Therapeutics and I sat down to discuss Sangamo’s plans for its in-house AAV manufacturing facility and the major benefits the facility will bring to genomic medicine and the sector at large.
Expression Therapeutics’ In-House Manufacturing Model — How And Why
Expression Therapeutics is building its own clean room. Here's why.
The Case For In-House Manufacturing Of Cell Therapies
Partnering with CMOS and CDMOs does not always make the most cost-effective sense especially when speed to clinical trial is most important.
Driving Diversity And Inclusion In Life Sciences
Experts weigh in on actionable ways to develop, implement, and require a diverse and inclusive working environment that drives innovation and profitability in life sciences.
Dr. Levine’s ISCT 2020 Recap
I caught up with Dr. Levine on the recent ISCT 2020 meeting as well as the first-in-U.S. CRISPR-edited immune cells.
Philadelphia As A Cell & Gene Therapy Hub
Saul Behar, Senior Vice President, Advancement and Strategic Initiatives at University City Science Center explains why Philadelphia has a unique combination of factors in terms of the strength of its assets around academic institutions, healthcare institutions, and its rich pharma legacy
The Greater Philadelphia Region As R&D, Manufacturing Hubs
Cell & Gene’s Chief Editor Erin Harris asks Claire Marrazzo Greenwood, Executive Director, CEO Council for Growth & VP, Leadership Engagement at Chamber of Commerce for Greater Philadelphia about the Greater Philadelphia region as an R&D, commercialization, and manufacturing hub.
Inside The Cell And Gene Therapy And Connected Health Workforce Analysis
Just recently, an independent study to analyze the current workforce landscape and assess the future talent needs of the Greater Philadelphia region’s cell and gene therapy and connected health sectors has found that this workforce is expected to grow between 35 percent to 94 percent in the next 10 years using mid-range growth estimates. The growth could be as much as 54 percent to 136 percent using high-range growth estimates.
Inside Protalix BioTherapeutics’ Phase 3 BRIDGE Study
Protalix BioTherapeutics the significance of the positive topline results from the Phase III BRIDGE open-label switch-over study.